Shang J , Ye G , Shi K , Wan Y , Luo C , Aihara H , et al . Structural basis of receptor recognition by SARS-CoV-2 . Nature . 2020 ; 581 ( 7807 ): 221 - 4 .

Wu JT , Leung K , Leung GM . Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study . Lancet . 2020 ; 395 ( 10225 ): 689 - 97 .

Nishiura H , Linton NM , Akhmetzhanov AR . Initial cluster of novel coronavirus (2019-nCoV) infections in Wuhan, China is consistent with substantial human-to-human transmission . J Clin Med . 2020 ; 9 ( 2 ): 488 .

Zhou P , Yang XL , Wang XG , Hu B , Zhang L , Zhang W , et al . A pneumonia outbreak associated with a new coronavirus of probable bat origin . Nature . 2020 ; 579 ( 7798 ): 270 - 3 .

Coronaviridae Study Group of the International Committee on Taxonomy of Viruses . The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2 . Nat Microbiol . 2020 ; 5 ( 4 ): 536 - 44 .

Zhu N , Zhang D , Wang W , Li X , Yang B , Song J , et al . A novel coronavirus from patients with pneumonia in China, 2019 . N Engl J Med . 2020 ; 382 ( 8 ): 727 - 33 .

Ge G , Lu Y , Qu X , Zhao W , Dong X . Muscle-inspired self-healing hydrogels for strain and temperature sensor . ACS Nano . 2019 ; 14 ( 1 ): 218 - 28 .

Wang J , Li P , Yu Y , Fu Y , Jiang H , Lu M , et al . Pulmonary surfactant–biomimetic nanoparticles potentiate heterosubtypic influenza immunity . Science . 2020 ; 367 ( 6480 ): eaau0810 .

Liu X , Wei D , Zhong J , Ma M , Zhou J , Peng X , et al . Electrospun nanofibrous P(DLLA-CL) balloons as calcium phosphate cement filled containers for bone repair: in vitro and in vivo studies . ACS Appl Mater Interfaces . 2015 ; 7 ( 33 ): 18540 - 52 .

Zhao XH , Peng XL , Gong HL , Wei DX . Osteogenic differentiation system based on biopolymer nanoparticles for stem cells in simulated microgravity . Biomed Mater . 2021 ; 16 ( 4 ): 044102 .

Guo YR , Cao QD , Hong ZS , Tan YY , Chen SD , Jin HJ , et al . The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status . Mil Med Res . 2020 ; 7 ( 1 ): 11 .

Chen Y , Liu Q , Guo D . Emerging coronaviruses: genome structure, replication, and pathogenesis . J Med Virol . 2020 ; 92 ( 4 ): 418 - 23 .

Huang C , Wang Y , Li X , Ren L , Zhao J , Hu Y , et al . Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China . Lancet . 2020 ; 395 ( 10223 ): 497 - 506 .

Paraskevis D , Kostaki EG , Magiorkinis G , Panayiotakopoulos G , Sourvinos G , Tsiodras S . Full-genome evolutionary analysis of the novel corona virus (2019-nCoV) rejects the hypothesis of emergence as a result of a recent recombination event . Infect Genet Evol . 2020 ; 79 : 104212 .

Banerjee A , Kulcsar K , Misra V , Frieman M , Mossman K . Bats and coronaviruses . Viruses . 2019 ; 11 ( 1 ): 41 .

Han HJ , Wen HL , Zhou CM , Chen FF , Luo LM , Liu JW , et al . Bats as reservoirs of severe emerging infectious diseases . Virus Res . 2015 ; 205 : 1 - 6 .

Wang D , Hu B , Hu C , Zhu F , Liu X , Zhang J , et al . Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China . JAMA . 2020 ; 323 ( 11 ): 1061 - 9 .

Chen H , Guo J , Wang C , Luo F , Yu X , Zhang W , et al . Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records . Lancet . 2020 ; 395 ( 10226 ): 809 - 15 .

Yadav T , Saxena SK . Transmission cycle of SARS-CoV and SARS-CoV-2 . In: Saxena S , editor . Coronavirus disease 2019 (COVID-19). Medical virology: from pathogenesis to disease control . Singapore : Springer ; 2020 . p. 33 – 42 .

Zhong P , Xu J , Yang D , Shen Y , Wang L , Feng Y , et al . COVID-19-associated gastrointestinal and liver injury: clinical features and potential mechanisms . Signal Transduct Target Ther . 2020 ; 5 ( 1 ): 256 .

Peiris JS , Chu CM , Cheng VC , Chan KS , Hung IF , Poon LL , et al . Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study . Lancet . 2003 ; 361 ( 9371 ): 1767 - 72 .

Yin W , Mao C , Luan X , Shen DD , Shen Q , Su H , et al . Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir . Science . 2020 ; 368 ( 6498 ): 1499 - 504 .

Wu F , Zhao S , Yu B , Chen YM , Wang W , Song ZG , et al . A new coronavirus associated with human respiratory disease in China . Nature . 2020 ; 579 ( 7798 ): 265 - 9 .

Chan JFW , Kok KH , Zhu Z , Chu H , Yuen KY . Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan . Emerg Microbes Infect . 2020 ; 9 ( 1 ): 221 - 36 .

Wang H , Li X , Li T , Zhang S , Liu J . The genetic sequence, origin, and diagnosis of SARS-CoV-2 . Eur J Clin Microbiol Infect Dis . 2020 ; 39 ( 9 ): 1629 - 35 .

de Haan CAM , Rottier P . Hosting the severe acute respiratory syndrome coronavirus: specific cell factors required for infection . Cell Microbiol . 2006 ; 8 ( 8 ): 1211 - 8 .

Robbiani DF , Gaebler C , Muecksch F , Lorenzi JCC , Wang Z , Cho A , et al . Convergent antibody responses to SARS-CoV-2 in convalescent individuals . Nature . 2020 ; 584 ( 7821 ): 437 - 42 .

Ju B , Zhang Q , Ge J , Wang R , Sun J , Ge X , et al . Human neutralizing antibodies elicited by SARS-CoV-2 infection . Nature . 2020 ; 584 ( 7819 ): 115 - 9 .

Xu X , Chen P , Wang J , Feng J , Zhou H , Li X , et al . Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission . Sci Chin Life Sci . 2020 ; 63 ( 3 ): 457 - 60 .

Lehrer S , Rheinstein PH . Ivermectin docks to the SARS-CoV-2 spike receptor-binding domain attached to ACE2 . In vivo . 2020 ; 34 ( 5 ): 3023 - 6 .

Letko M , Marzi A , Munster V . Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B beta-coronaviruses . Nat Microbiol . 2020 ; 5 ( 4 ): 562 - 9 .

Jiang S , Shi ZL . The first disease X is caused by a highly transmissible acute respiratory syndrome coronavirus . Virol Sin . 2020 ; 35 ( 3 ): 263 - 5 .

Liu X , Wang XJ . Potential inhibitors against 2019-nCoV coronavirus M protease from clinically approved medicines . J Genet Genom . 2020 ; 47 ( 2 ): 119 - 21 .

Benvenuto D , Giovanetti M , Ciccozzi A , Spoto S , Angeletti S , Ciccozzi M . The 2019-new coronavirus epidemic: evidence for virus evolution . J Med Virol . 2020 ; 92 ( 4 ): 455 - 9 .

Song W , Gui M , Wang X , Xiang Y . Cryo-EM structure of the SARS coronavirus spike glycoprotein in complex with its host cell receptor ACE2 . PLoS Pathog . 2018 ; 14 ( 8 ): e1007236 .

Shang J , Wan Y , Luo C , Ye G , Geng Q , Auerbach A , et al . Cell entry mechanisms of SARS-CoV-2 . Proc Natl Acad Sci U S A . 2020 ; 117 ( 21 ): 202003138 .

Wrapp D , Wang N , Corbett KS , Goldsmith JA , Hsieh CL , Abiona O , et al . Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation . Science . 2020 ; 367 ( 6483 ): 1260 - 3 .

Yan R , Zhang Y , Li Y , Xia L , Guo Y , Zhou Q . Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2 . Science . 2020 ; 367 ( 6485 ): 1444 - 8 .

Wang B , Wang L , Kong X , Geng J , Xiao D , Ma C , et al . Long-term coexistence of SARS-CoV-2 with antibody response in COVID-19 patients . J Med Virol . 2020 ; 92 ( 9 ): 1684 - 9 .

Bussani R , Schneider E , Zentilin L , Collesi C , Ali H , Braga L , et al . Persistence of viral RNA, pneumocyte syncytia and thrombosis are hallmarks of advanced COVID-19 pathology . EBioMedicine . 2020 ; 61 : 103104 .

Leung K , Shum MH , Leung GM , Lam TT , Wu JT . Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-2 in the United Kingdom, October to November 2020 . Euro Surveill . 2021 ; 26 ( 1 ): 2002106 .

Volz E , Mishra S , Chand M , Barrett JC , Johnson R , Geidelberg L , et al . Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England . Nature . 2021 ; 593 ( 7858 ): 266 - 269 .

Giandhari J , Pillay S , Wilkinson E , Tegally H , Sinayskiy I , Schuld M , et al . Early transmission of SARS-CoV-2 in South Africa: An epidemiological and phylogenetic report . Int J Infect Dis . 2021 ; 103 : 234 - 41 .

Admou B , Hazime R , Brahim I , El Adib AR . Influencing factors of SARS-CoV-2 spread in Africa . J Glob Health . 2020 ; 10 ( 2 ): 020331 .

Makoni M . South Africa responds to new SARS-CoV-2 variant . Lancet . 2021 ; 397 ( 10271 ): 267 .

Galloway SE , Paul P , MacCannell DR , Johansson MA , Brooks JT , MacNeil A , et al . Emergence of SARS-CoV-2 B.1.1.7 Lineage - United States, December 29, 2020-January 12, 2021 . MMWR Morb Mortal Wkly Rep . 2021 ; 70 ( 3 ): 95 - 9 .

Cherian S , Potdar V , Jadhav S , Yadav P , Gupta N , Das M , et al . SARS-CoV-2 spike mutations, L452R, T478K, E484Q and P681R, in the second wave of COVID-19 in Maharashtra, India . Microorganisms . 2021 ; 9 ( 7 ): 1542 .

Yadav PD , Sapkal GN , Abraham P , Ella R , Deshpande G , Patil DY , et al . Neutralization of variant under investigation B.1.617 with sera of BBV152 vaccinees . Clin Infect Dis . 2021 : ciab411 .

Chen J , Wang R , Wang M , Wei GW . Mutations strengthened SARS-CoV-2 infectivity . J Mol Biol . 2020 ; 432 ( 19 ): 5212 - 26 .

Daniloski Z , Jordan TX , Ilmain JK , Guo X , Bhabha G , tenOever BR , et al . The Spike D614G mutation increases SARS-CoV-2 infection of multiple human cell types . Elife . 2021 ; 10 : e65365 .

Li Q , Wu J , Nie J , Zhang L , Hao H , Liu S , et al . The impact of mutations in SARS-CoV-2 spike on viral infectivity and antigenicity . Cell . 2020 ; 182 ( 5 ): 1284-94.e9 .

Wang R , Chen J , Gao K , Hozumi Y , Yin C , Wei GW . Analysis of SARS-CoV-2 mutations in the United States suggests presence of four substrains and novel variants . Commun Biol . 2021 ; 4 ( 1 ): 228 .

Wang J , Liao Y , Wang X , Li Y , Jiang D , He J , et al . Incidence of novel coronavirus (2019-nCoV) infection among people under home quarantine in Shenzhen, China . Travel Med Infect Dis . 2020 ; 37 : 101660 .

Chen N , Zhou M , Dong X , Qu J , Gong F , Han Y , et al . Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study . Lancet . 2020 ; 395 ( 10223 ): 507 - 13 .

Ackermann M , Verleden SE , Kuehnel M , Haverich A , Welte T , Laenger F , et al . Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in COVID-19 . N Engl J Med . 2020 ; 383 ( 2 ): 120 - 8 .

Caddy S . Developing a vaccine for COVID-19 . BMJ . 2020 ; 369 : m1790 .

Uddin M , Mustafa F , Rizvi TA , Loney T , Senok AC . SARS-CoV-2/COVID-19: viral genomics, epidemiology, vaccines, and therapeutic interventions . Viruses . 2020 ; 12 ( 5 ): 526 .

Ramírez-Mora T , Retana-Lobo C , Reyes-Carmona J . COVID-19: perspectives on the pandemic and its incidence in dentistry . Odovtos Int J Dent Sci . 2020 ; 22 ( 3 ): 22 - 42 .

Graham RL , Donaldson EF , Baric RS . A decade after SARS: strategies for controlling emerging coronaviruses . Nat Rev Microbiol . 2013 ; 11 ( 12 ): 836 - 48 .

Pardi N , Hogan MJ , Porter FW , Weissman D . mRNA vaccines–a new era in vaccinology . Nat Rev Drug Discov . 2018 ; 17 ( 4 ): 261 .

Sadoff J , Le Gars M , Shukarev G , Heerwegh D , Truyers C , De Groot AM , et al . Interim results of a phase 1-2a trial of Ad26. COV2. S COVID-19 vaccine . N Engl J Med . 2021 ; 384 ( 19 ): 1824 - 35 .

Folegatti PM , Ewer KJ , Aley PK , Angus B , Becker S , Belij-Rammerstorfer S , et al . Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial . Lancet . 2020 ; 396 ( 10249 ): 467 - 78 .

Ramasamy MN , Minassian AM , Ewer KJ , Flaxman AL , Folegatti PM , Owens DR , et al . Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial . Lancet . 2020 ; 396 ( 10267 ): 1979 - 93 .

Voysey M , Clemens SC , Madhi SA , Weckx LY , Folegatti PM , Aley PK , et al . Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK . Lancet . 2021 ; 397 ( 10269 ): 99 - 111 .

Barrett JR , Belij-Rammerstorfer S , Dold C , Ewer KJ , Folegatti PM , Gilbride C , et al . Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses . Nat Med . 2021 ; 27 ( 2 ): 279 - 88 .

Ewer KJ , Barrett JR , Belij-Rammerstorfer S , Sharpe H , Makinson R , Morter R , et al . T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial . Nat Med . 2021 ; 27 ( 2 ): 270 - 8 .

Voysey M , Costa Clemens SA , Madhi SA , Weckx LY , Folegatti PM , Aley PK , et al . Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials . Lancet . 2021 ; 397 ( 10277 ): 881 - 91 .

Zhu FC , Li YH , Guan XH , Hou LH , Wang WJ , Li JX , et al . Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, firstin-human trial . Lancet . 2020 ; 395 ( 10240 ): 1845 - 54 .

Zhu FC , Guan XH , Li YH , Huang JY , Jiang T , Hou LH , et al . Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial . Lancet . 2020 ; 396 ( 10249 ): 479 - 88 .

Logunov DY , Dolzhikova IV , Zubkova OV , Tukhvatullin AI , Shcheblyakov DV , Dzharullaeva AS , et al . Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia . Lancet . 2020 ; 396 ( 10255 ): 887 - 97 .

Abbink P , Lemckert AAC , Ewald BA , Lynch DM , Denholtz M , Smits S , et al . Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D . J Virol . 2007 ; 81 ( 9 ): 4654 - 63 .

Oliver SE , Gargano JW , Marin M , Wallace M , Curran KG , Chamberland M , et al . The advisory committee on immunization practices’ interim recommendation for use of Pfizer-BioNTech COVID-19 Vaccine - United States, December 2020 . MMWR Morb Mortal Wkly Rep . 2020 ; 69 ( 50 ): 1922 - 4 .

Apostolidis SA , Kakara M , Painter MM , Goel RR , Mathew D , Lenzi K , et al . Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy . Nat Med . 2021 . https://doi.org/10.1038/s41591-021-01507-2 https://doi.org/10.1038/s41591-021-01507-2 .

Mulligan MJ , Lyke KE , Kitchin N , Absalon J , Gurtman A , Lockhart S , et al . Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults . Nature . 2020 ; 586 ( 7830 ): 589 - 93 .

Roncati L , Corsi L . Nucleoside-modified messenger RNA COVID-19 vaccine platform . J Med Virol . 2021 ; 93 ( 7 ): 4054 - 7 .

Sahin U , Muik A , Derhovanessian E , Vogler I , Kranz LM , Vormehr M , et al . COVID-19 vaccine BNT162b1 elicits human antibody and TH 1 T cell responses . Nature . 2020 ; 586 ( 7830 ): 594 - 9 .

Walsh EE , Frenck RW Jr , Falsey AR , Kitchin N , Absalon J , Gurtman A , et al . Safety and immunogenicity of two RNA-based COVID-19 vaccine candidates . N Engl J Med . 2020 ; 383 ( 25 ): 2439 - 50 .

Ortega Rodríguez NR , Audícana Berasategui MT , de la Hoz CB , Valero SA . The century of mRNA vaccines: COVID-19 vaccines and allergy . J Investig Allergol Clin Immunol . 2021 ; 31 ( 1 ): 89 - 91 .

Mukhopadhyay L , Yadav PD , Gupta N , Mohandas S , Patil DY , Shete-Aich A , et al . Comparison of the immunogenicity & protective efficacy of various SARS-CoV-2 vaccine candidates in non-human primates . Indian J Med Res . 2021 ; 153 ( 1 & 2 ): 93 - 114 .

Sahin U , Muik A , Vogler I , Derhovanessian E , Kranz LM , Vormehr M , et al . BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans . Nature . 2021 ; 595 ( 7868 ): 572 - 7 .

Muik A , Wallisch AK , Sänger B , Swanson KA , Mühl J , Chen W , et al . Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera . Science . 2021 ; 371 ( 6534 ): 1152 - 3 .

Li J , Hui A , Zhang X , Yang Y , Tang R , Ye H , et al . Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study . Nat Med . 2021 ; 27 ( 6 ): 1062 - 70 .

India Education Diary Bureau Admin . Moderna’S COVID-19 vaccine candidate meets its primary efficacy endpoint in the first interim analysis of the phase 3 COVE study . https://indiaeducationdiary.in/modernas-covid-19-vaccine-candidate-meets-its-primary-efficacyendpoint-in-the-first-interim-analysis-of-the-phase-3-cove-study/ https://indiaeducationdiary.in/modernas-covid-19-vaccine-candidate-meets-its-primary-efficacyendpoint-in-the-first-interim-analysis-of-the-phase-3-cove-study/ . Accessed 16 Nov 2020 .

Jackson LA , Anderson EJ , Rouphael NG , Roberts PC , Makhene M , Coler RN , et al . An mRNA vaccine against SARS-CoV-2–preliminary report . N Engl J Med . 2020 ; 383 ( 20 ): 1920 - 31 .

Corbett KS , Edwards DK , Leist SR , Abiona OM , Boyoglu-Barnum S , Gillespie RA , et al . SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness . Nature . 2020 ; 586 ( 7830 ): 567 - 71 .

Wang F , Kream RM , Stefano GB . An evidence based perspective on mRNA-SARS-CoV-2 vaccine development . Med Sci Monit . 2020 ; 26 : e924700 .

Baden LR , El Sahly HM , Essink B , Kotloff K , Frey S , Novak R , et al . Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine . N Engl J Med . 2021 ; 384 ( 5 ): 403 - 16 .

Oliver SE , Gargano JW , Marin M , Wallace M , Curran KG , Chamberland M , et al . The advisory committee on immunization practices’ interim recommendation for use of moderna COVID-19 vaccine - United States, December 2020 . MMWR Morb Mortal Wkly Rep . 2021 ; 69 ( 5152 ): 1653 - 6 .

Mohandas S , Yadav PD , Shete-Aich A , Abraham P , Vadrevu KM , Sapkal G , et al . Immunogenicity and protective efficacy of BBV152, whole virion inactivated SARS- CoV-2 vaccine candidates in the Syrian hamster model . iScience . 2021 ; 24 ( 2 ): 102054 .

Sapkal G , Yadav PD , Ella R , Abraham P , Patil DY , Gupta N , et al . Neutralization of VUI B.1.1.28 P2 variant with sera of COVID-19 recovered cases and recipients of Covaxin an inactivated COVID-19 vaccine . J Travel Med . 2021 ; 28 ( 7 ): taab077 .

Ella R , Vadrevu KM , Jogdand H , Prasad S , Reddy S , Sarangi V , et al . Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial . Lancet Infect Dis . 2021 ; 21 ( 5 ): 637 - 46 .

Grigoryan L , Pulendran B . The immunology of SARS-CoV-2 infections and vaccines . Semin Immunol . 2020 ; 50 : 101422 .

Fadlyana E , Rusmil K , Tarigan R , Rahmadi AR , Prodjosoewojo S , Sofiatin Y , et al . A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18–59 years: an interim analysis in Indonesia . Vaccine . 2021 ; 39 ( 44 ): 6520 - 8 .

Karamese M , Tutuncu EE . The effectiveness of inactivated SARS-CoV-2 vaccine (CoronaVac) on antibody response in participants aged 65 years and older . J Med Virol . 2022 ; 94 ( 1 ): 173 - 7 .

Xia S , Duan K , Zhang Y , Zhao D , Zhang H , Xie Z , et al . Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials . JAMA . 2020 ; 324 ( 10 ): 951 - 60 .

Isho B , Abe KT , Zuo M , Jamal AJ , Rathod B , Wang JH , et al . Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients . Sci Immunol . 2020 ; 5 ( 52 ): eabe5511 .

Weisblum Y , Schmidt F , Zhang F , DaSilva J , Poston D , Lorenzi JC , et al . Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants . Elife . 2020 ; 9 : e61312 .

Richmond PC , Hatchuel L , Pacciarini F , Hu B , Smolenov I , Li P , et al . Persistence of the immune responses and cross-neutralizing activity Peng et al . Military Medical Research (2021) 8:67 Page 28 of 31 with variants of concern following two doses of adjuvanted SCB-2019 COVID-19 vaccine . J Infect Dis . 2021 : jiab447 .

Richmond P , Hatchuel L , Dong M , Ma B , Hu B , Smolenov I , et al . Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial . Lancet . 2021 ; 397 ( 10275 ): 682 - 94 .

Keech C , Albert G , Cho I , Robertson A , Reed P , Neal S , et al . Phase 1–2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine . N Engl J Med . 2020 ; 383 ( 24 ): 2320 - 32 .

Huang WC , Zhou S , He X , Chiem K , Mabrouk MT , Nissly RH , et al . SARS-CoV-2 RBD neutralizing antibody induction is enhanced by particulate vaccination . Adv Mater . 2020 ; 32 ( 50 ): e2005637 .

Ma X , Zou F , Yu F , Li R , Yuan Y , Zhang Y , et al . Nanoparticle vaccines based on the receptor binding domain (RBD) and heptad repeat (HR) of SARS-CoV-2 elicit robust protective immune responses . Immunity . 2020 ; 53 ( 6 ): 1315-30.e9 .

Guebre-Xabier M , Patel N , Tian JH , Zhou B , Maciejewski S , Lam K , et al . NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge . Vaccine . 2020 ; 38 ( 50 ): 7892 - 6 .

Zhang N , Li C , Hu Y , Li K , Liang J , Wang L , et al . Current development of COVID-19 diagnostics, vaccines and therapeutics . Microbes Infect . 2020 ; 22 ( 6–7 ): 231 - 5 .

Tenforde MW , Self WH , Adams K , Gaglani M , Ginde AA , McNeal T , et al . Association between mRNA vaccination and COVID-19 hospitalization and disease severity . JAMA . 2021 . https://doi.org/10.1001/jama.2021.19499 https://doi.org/10.1001/jama.2021.19499 .

Polack FP , Thomas SJ , Kitchin N , Absalon J , Gruber WC . Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine . N Engl J Med . 2020 ; 383 ( 27 ): 2603 - 15 .

Whitehead SS , Blaney JE , Durbin AP , Murphy BR . Prospects for a dengue virus vaccine . Nat Rev Microbiol . 2007 ; 5 ( 7 ): 518 - 28 .

Corbett KS , Flynn B , Foulds KE , Francica JR , Graham BS . Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates . N Engl J Med . 2020 ; 383 ( 16 ): 1544 - 55 .

Widge AT , Rouphael NG , Jackson LA , Anderson EJ , Beigel JH . Durability of responses after SARS-CoV-2 mRNA-1273 vaccination . N Engl J Med . 2021 ; 384 ( 1 ): 80 - 2 .

Anderson EJ , Rouphael NG , Widge AT , Jackson LA , Roberts PC , Makhene M , et al . Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults . N Engl J Med . 2020 ; 383 ( 25 ): 2427 - 38 .

Logunov DY , Dolzhikova IV , Shcheblyakov DV , Tukhvatulin AI , Zubkova OV , Dzharullaeva AS , et al . Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia . Lancet . 2021 ; 397 ( 10275 ): 671 - 81 .

Naygovzina NB , Khabriev RU , Krasheninnikov AE , Matveev AV . [The organizational aspects of security support of participants of clinical testing of vaccine "Gam-COVID-Vac"] . Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med . 2021 ; 29 ( 1 ): 5 - 13 (Article in Russian) .

Wang ZJ , Zhang HJ , Lu J , Xu KW , Peng C , Guo J , et al . Low toxicity and high immunogenicity of an inactivated vaccine candidate against COVID-19 in different animal models . Emerg Microbes Infect . 2020 ; 9 ( 1 ): 2606 - 18 .

Sharma O , Sultan AA , Ding H , Triggle CR . A review of the progress and challenges of developing a vaccine for COVID-19 . Front Immunol . 2020 ; 11 : 585354 .

Ledford H . Oxford COVID-vaccine paper highlights lingering unknowns about results . Nature . 2020 ; 588 ( 7838 ): 378 - 9 .

Knoll MD , Wonodi C . Oxford-AstraZeneca COVID-19 vaccine efficacy . Lancet . 2021 ; 397 ( 10269 ): 72 - 4 .

Mishra SK , Tripathi T . One year update on the COVID-19 pandemic: where are we now? Acta Trop . 2021 ; 214 : 105778 .

Matar E , Manser D , Spies JM , Worthington JM , Parratt KL . Acute hemichorea-hemiballismus following COVID-19 (AZD1222) vaccination . Mov Disord . 2021 . https://doi.org/10.1002/mds.28796 https://doi.org/10.1002/mds.28796 .

Xia S , Liu M , Wang C , Xu W , Lan Q , Feng S , et al . Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion . Cell Res . 2020 ; 30 ( 4 ): 343 - 55 .

Wu S , Zhong G , Zhang J , Shuai L , Chen W . A single dose of an adenovirus-vectored vaccine provides protection against SARS-CoV-2 challenge . Nat Commun . 2020 ; 11 ( 1 ): 4081 .

Bos R , Rutten L , van der Lubbe JEM , Bakkers MJG , Hardenberg G , Wegmann F , et al . Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses . NPJ Vaccines . 2020 ; 5 : 91 .

Mercado NB , Zahn R , Wegmann F , Loos C , Dan HB . Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques . Nature . 2020 ; 586 ( 7830 ): 583 - 8 .

Stephenson KE , Le Gars M , Sadoff J , de Groot AM , Heerwegh D , Truyers C , et al . Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19 . JAMA . 2021 ; 325 ( 15 ): 1535 - 44 .

Sadoff J , Gray G , Vandebosch A , Cárdenas V , Shukarev G , Grinsztejn B , et al . Safety and efficacy of single-dose Ad26.COV2.S vaccine against COVID-19 . N Engl J Med . 2021 ; 384 ( 23 ): 2187 - 201 .

George G , Friedman KD , Curtis BR , Lind SE . Successful treatment of Thrombotic thrombocytopenia with cerebral sinus venous thrombosis following Ad26.COV2.S vaccination . Am J Hematol . 2021 ; 96 ( 8 ): E301 - 3 .

Muir KL , Kallam A , Koepsell SA , Gundabolu K . Thrombotic thrombocytopenia after Ad26.COV2.S vaccination . N Engl J Med . 2021 ; 384 ( 20 ): 1964 - 5 .

Doroftei B , Ciobica A , Ilie OD , Maftei R , Ilea C . Mini-review discussing the reliability and efficiency of COVID-19 vaccines . Diagnostics (Basel) . 2021 ; 11 ( 4 ): 579 .

Cao Y , Yisimayi A , Bai Y , Huang W , Li X , Zhang Z , et al . Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines . Cell Res . 2021 ; 31 ( 7 ): 732 - 41 .

Yang S , Li Y , Dai L , Wang J , He P , Li C , et al . Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials . Lancet Infect Dis . 2021 ; 21 ( 8 ): 1107 - 19 .

Wang H , Zhang Y , Huang B , Deng W , Yang X . Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2 . Cell . 2020 ; 182 ( 3 ): 713-721.e9 .

Huang B , Dai L , Wang H , Hu Z , Yang X , Tan W , et al . Serum sample neutralisation of BBIBP-CorV and ZF2001 vaccines to SARS-CoV-2 501Y. V2 . Lancet Microbe . 2021 ; 2 ( 7 ): e285 .

Al Kaabi N , Zhang Y , Xia S , Yang Y , Al Qahtani MM , Abdulrazzaq N , et al . Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial . JAMA . 2021 ; 326 ( 1 ): 35 - 45 .

Zhang Y , Zeng G , Pan H , Li C , Hu Y , Chu K , et al . Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial . Lancet Infect Dis . 2021 ; 21 ( 2 ): 181 - 92 .

Thiagarajan K . What do we know about India’s Covaxin vaccine? BMJ . 2021 ; 373 : n997 .

Gao Q , Bao L , Mao H , Wang L , Xu K , Yang M , et al . Development of an inactivated vaccine candidate for SARS-CoV-2 . Science . 2020 ; 369 ( 6499 ): 77 - 81 .

van Doremalen N , Lambe T , Spencer A , Belij-Rammerstorfer S , Purushotham JN , Port JR , et al . ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques . Nature . 2020 ; 586 ( 7830 ): 578 - 82 .

Chauhan A , Agarwal A , Jaiswal N , Singh M . ChAdOx1 nCoV-19 vaccine for SARS-CoV-2 . Lancet . 2020 ; 396 ( 10261 ): 1485 - 6 .

Ashokkumar M , Ajayan PM . Materials science perspective of multifunctional materials derived from collagen . Int Mater Rev . 2021 ; 66 ( 3 ): 160 - 87 .

Kandeel M , Al-Taher A , Park BK , Kwon HJ , Al-Nazawi M . A pilot study of the antiviral activity of anionic and cationic polyamidoamine dendrimers against the middle east respiratory syndrome coronavirus . J Med Virol . 2020 ; 92 ( 9 ): 1665 - 70 .

Han B , Song Y , Li C , Yang W , Ma Q , Jiang Z , et al . Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial . Lancet Infect Dis . 2021 ; S1473–3099 ( 21 ): 00319 - 24 .

Che Y , Liu X , Pu Y , Zhou M , Zhao Z , Jiang R , et al . Randomized, double-blinded and placebo-controlled phase II trial of an inactivated SARS-CoV-2 vaccine in healthy adults . Clin Infect Dis . 2020 : ciaa1703 .

Li XN , Huang Y , Wang W , Jing QL , Zhang CH , Qin PZ , et al . Effectiveness of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: a test-negative case-control real-world study . Emerg Microbes Infect . 2021 ; 10 ( 1 ): 1751 - 9 .

Zhang MX , Zhang TT , Shi GF , Cheng FM , Zheng YM , Tung TH , et al . Safety of an inactivated SARS-CoV-2 vaccine among healthcare workers in China . Expert Rev Vaccines . 2021 ; 20 ( 7 ): 891 - 8 .

Wu Z , Hu Y , Xu M , Chen Z , Yang W , Jiang Z , et al . Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial . Lancet Infect Dis . 2021 ; 21 ( 6 ): 803 - 12 .

Bueno SM , Abarca K , González PA , Gálvez NMS , Soto JA , Duarte LF , et al . Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in a subgroup of healthy adults in Chile . Clin Infect Dis . 2021 : ciab823 .

Akova M , Unal S . A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial . Trials . 2021 ; 22 ( 1 ): 276 .

Saleh AA , Saad MA , Ryan I , Amin M , Shindy MI , Hassan WA , et al . Safety and immunogenicity evaluation of inactivated whole-virus-SARS-COV-2 as emerging vaccine development in Egypt . Antib Ther . 2021 ; 4 ( 3 ): 135 - 43 .

Xia S , Zhang Y , Wang Y , Wang H , Yang Y , Gao GF , et al . Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial . Lancet Infect Dis . 2021 ; 21 ( 1 ): 39 - 51 .

Palacios R , Patiño EG , de Oliveira PR , Conde MTRP , Batista AP , Zeng G , et al . Double-blind, randomized, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of treating healthcare professionals with the adsorbed COVID-19 (inactivated) vaccine manufactured by sinovac - PROFISCOV: a structured summary of a study protocol for a randomised controlled trial . Trials . 2020 ; 21 ( 1 ): 853 .

Guo W , Duan K , Zhang Y , Yuan Z , Zhang YB , Wang Z , et al . Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18 years or older: A randomized, double-blind, placebo-controlled, phase 1/2 trial . EClinicalMedicine . 2021 ; 38 : 101010 .

Heininger U . Efficacy of single-dose Ad26.COV2.S vaccine against COVID-19 . N Engl J Med . 2021 ; 385 ( 3 ): 288 .

Heath PT , Galiza EP , Baxter DN , Boffito M , Browne D , Burns F , et al . Safety and efficacy of NVX-CoV2373 COVID-19 vaccine . N Engl J Med . 2021 ; 385 ( 13 ): 1172 - 83 .

Tré-Hardy M , Cupaiolo R , Wilmet A , Beukinga I , Blairon L . Waning antibodies in SARS-CoV-2 naïve vaccinees: Results of a three-month interim analysis of ongoing immunogenicity and efficacy surveillance of the mRNA-1273 vaccine in healthcare workers . J Infect . 2021 ; 83 ( 3 ): 381 - 412 .

Salvagno GL , Henry BM , Pighi L , De Nitto S , Gianfilippi GL , Lippi G . Three-month analysis of total humoral response to Pfizer BNT162b2 mRNA COVID-19 vaccination in healthcare workers . J Infect . 2021 ; 83 ( 2 ): e4 - 5 .

Kremsner PG , Mann P , Kroidl A , Leroux-Roels I , Schindler C , Gabor JJ , et al . Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2: A phase 1 randomized clinical trial . Wien Klin Wochenschr . 2021 ; 133 ( 17–18 ): 931 - 41 .

Shrivastava T , Singh B , Rizvi ZA , Verma R , Goswami S , Vishwakarma P , et al . Comparative immunomodulatory evaluation of the receptor binding domain of the SARS-CoV-2 spike protein; a potential vaccine candidate which imparts potent humoral and Th1 type immune response in a mouse model . Front Immunol . 2021 ; 12 : 641447 .

Bisgin A , Sanlioglu AD , Eksi YE , Griffith TS , Sanlioglu S . Current update on severe acute respiratory syndrome coronavirus 2 vaccine development with a special emphasis on gene therapy viral vector design and construction for vaccination . Hum Gene Ther . 2021 ; 32 ( 11–12 ): 541 - 62 .

Ryzhikov AB , Ryzhikov EA , Bogryantseva MP , Danilenko ED , Imatdinov IR , Nechaeva EA , et al . Immunogenicity and protectivity of the peptide vaccine against SARS-CoV-2 . Ann Russian Acad Med Sci . 2021 ; 76 ( 1 ): 5 - 19 .

Zhang NN , Li XF , Deng YQ , Zhao H , Huang YJ , Yang G , et al . A Thermostable mRNA Vaccine against COVID-19 . Cell . 2020 ; 182 ( 5 ): 1271-83.e16 .

Hsieh SM , Liu WD , Huang YS , Lin YJ , Hsieh EF , Lian WC , et al . Safety and immunogenicity of a recombinant stabilized prefusion SARS-CoV-2 spike protein vaccine (MVC COV1901) adjuvanted with CpG 1018 and aluminum hydroxide in healthy adults: a phase 1, dose-escalation study . EClinicalMedicine . 2021 ; 38 : 100989 .

Choi A , Koch M , Wu K , Chu L , Ma L , Hill A , et al . Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis . Nat Med . 2021 . https://doi.org/10.1038/s41591-021-01527-y https://doi.org/10.1038/s41591-021-01527-y .

Song F , Fux R , Provacia LB , Volz A , Eickmann M , Becker S , et al . Middle east respiratory syndrome coronavirus spike protein delivered by modified vaccinia virus Ankara efficiently induces virus-neutralizing antibodies . J Virol . 2013 ; 87 ( 21 ): 11950 - 4 .

Lillie PJ , Berthoud TK , Powell TJ , Lambe T , Mullarkey C , Spencer AJ , et al . Preliminary assessment of the efficacy of a t-cell-based influenza vaccine, MVA-NP+ M1, in humans . Clin Infect Dis . 2012 ; 55 ( 1 ): 19 - 25 .

Bart PA , Huang Y , Karuna ST , Chappuis S , Gaillard J , Kochar N , et al . HIV-specific humoral responses benefit from stronger prime in Phase Ib clinical trial . J Clin Invest . 2014 ; 124 ( 11 ): 4843 - 56 .

Hörner C , Schürmann C , Auste A , Ebenig A , Muraleedharan S , Dinnon KH , et al . A highly immunogenic and effective measles virus-based Th1-biased COVID-19 vaccine . Proc Natl Acad Sci USA . 2020 ; 117 ( 51 ): 32657 - 66 .

Zhu FC , Hou LH , Li JX , Wu SP , Liu P , Zhang GR , et al . Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial . Lancet . 2015 ; 385 ( 9984 ): 2272 - 9 .

Matsuda K , Huang J , Zhou T , Sheng Z , Kang BH , Ishida E , et al . Prolonged evolution of the memory B cell response induced by a replicating adenovirus-influenza H5 vaccine . Sci Immunol . 2019 ; 4 ( 34 ): eaau2710 .

Baden LR , Karita E , Mutua G , Bekker LG , Gray G , Page-Shipp L , et al . Assessment of the safety and immunogenicity of 2 novel vaccine platforms for HIV-1 prevention: a randomized trial . Ann Intern Med . 2016 ; 164 ( 5 ): 313 - 22 .

Garbutt M , Liebscher R , Wahl-Jensen V , Jones S , Möller P , Wagner R , et al . Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses . J Virol . 2004 ; 78 ( 10 ): 5458 - 65 .

Betancourt D , De Queiroz NM , Xia T , Ahn J , Barber GN . Cutting edge: innate immune augmenting vesicular stomatitis virus expressing Zika virus proteins confers protective immunity . J Immunol . 2017 ; 198 ( 8 ): 3023 - 8 .

Ma Y , Li J . Vesicular stomatitis virus as a vector to deliver virus-like particles of human norovirus: a new vaccine candidate against an important noncultivable virus . J Virol . 2011 ; 85 ( 6 ): 2942 - 52 .

Jiang X , Dalebout TJ , Bredenbeek PJ , Carrion R Jr , Brasky K , Patterson J , et al . Yellow fever 17D-vectored vaccines expressing Lassa virus GP1 and GP2 glycoproteins provide protection against fatal disease in guinea pigs . Vaccine . 2011 ; 29 ( 6 ): 1248 - 57 .

Bulcha JT , Wang Y , Ma H , Tai PWL , Gao G . Viral vector platforms within the gene therapy landscape . Signal Transduct Target Ther . 2021 ; 6 ( 1 ): 53 .

Wang Q , Finer MH . Second-generation adenovirus vectors . Nat Med . 1996 ; 2 ( 6 ): 714 - 6 .

Li JX , Hou LH , Meng FY , Wu SP , Hu YM , Liang Q , et al . Immunity duration of a recombinant adenovirus type-5 vector-based Ebola vaccine and a homologous prime-boost immunisation in healthy adults in China: final report of a randomised, double-blind, placebo-controlled, phase 1 trial . Lancet Glob health . 2017 ; 5 ( 3 ): e324 - 34 .

Kim E , Okada K , Kenniston T , Raj VS , Alhajri MM , Farag EA , et al . Immunogenicity of an adenoviral-based Middle East Respiratory Syndrome coronavirus vaccine in BALB/c mice . Vaccine . 2014 ; 32 ( 45 ): 5975 - 82 .

Milligan ID , Gibani MM , Sewell R , Clutterbuck EA , Campbell D , Plested E , et al . Safety and immunogenicity of novel adenovirus type 26–and modified vaccinia ankara–vectored ebola vaccines: a randomized clinical trial . JAMA . 2016 ; 315 ( 15 ): 1610 - 23 .

Abbink P , Larocca RA , Rafael A , Bricault CA , Moseley ET , Boyd M , et al . Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys . Science . 2016 ; 353 ( 6304 ): 1129 - 32 .

Tebas P , Yang S , Boyer JD , Reuschel EL , Patel A , Christensen-Quick A , et al . Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: a preliminary report of an open-label, phase 1 clinical trial . EClinicalMedicine . 2021 ; 31 : 100689 .

Yoo JH . What we do know and do not yet know about COVID-19 vaccines as of the beginning of the year 2021 . J Korean Med Sci . 2021 ; 36 ( 6 ): e54 .

Feldman RA , Fuhr R , Smolenov I , Ribeiro AM , Panther L , Watson M , et al . mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials . Vaccine . 2019 ; 37 ( 25 ): 3326 - 34 .

Schneeweiss A , Chabierski S , Salomo M , Delaroque N , Al-Robaiy S , Grunwald T , et al . A DNA vaccine encoding the E protein of West Nile virus is protective and can be boosted by recombinant domain DIII . Vaccine . 2011 ; 29 ( 37 ): 6352 - 7 .

Donnelly JJ , Wahren B , Liu MA . DNA vaccines: progress and challenges . J Immunol . 2005 ; 175 ( 2 ): 633 - 9 .

Li L , Petrovsky N . Molecular mechanisms for enhanced DNA vaccine immunogenicity . Expert Rev Vaccines . 2016 ; 15 ( 3 ): 313 - 29 .

Schalk JAC , Mooi FR , Berbers GAM , van Aerts LAGJM , Ovelgönne H , Kimman TG . Preclinical and clinical safety studies on DNA vaccines . Hum Vaccin . 2006 ; 2 ( 2 ): 45 - 53 .

Andrade VM , Christensen-Quick A , Agnes J , Tur J , Reed C , Kalia R , et al . INO-4800 DNA vaccine induces neutralizing antibodies and T cell activity against global SARS-CoV-2 variants . NPJ Vaccines . 2021 ; 6 ( 1 ): 121 .

Smith TR , Patel A , Ramos S , Elwood D , Zhu X , Yan J , et al . Immunogenicity of a DNA vaccine candidate for COVID-19 . Nat Commun . 2020 ; 11 ( 1 ): 2601 .

Robinson HL , Pertmer TM . DNA vaccines for viral infections: basic studies and applications . Adv Virus Res . 2000 ; 55 : 1 - 74 .

Alarcon JB , Waine GW , McManus DP . DNA vaccines: technology and application as anti-parasite and anti-microbial agents . Adv Parasitol . 1999 ; 42 : 343 - 410 .

Harmon BT , Aly AE , Padegimas L , Sesenoglu-Laird O , Cooper MJ , Waszczak BL . Intranasal administration of plasmid DNA nanoparticles yields successful transfection and expression of a reporter protein in rat brain . Gene Ther . 2014 ; 21 ( 5 ): 514 - 21 .

Schlake T , Thess A , Fotin-Mleczek M , Kallen KJ . Developing mRNA vaccine technologies . RNA Biol . 2012 ; 9 ( 11 ): 1319 - 30 .

Rauch S , Jasny E , Schmidt KE , Petsch B . New vaccine technologies to combat outbreak situations . Front Immunol . 2018 ; 9 : 1963 .

Ni H , Capodici J , Cannon G , Communi D , Boeynaems JM , Karikó K , et al . Extracellular mRNA induces dendritic cell activation by stimulating tumor necrosis factor-alpha secretion and signaling through a nucleotide receptor . J Biol Chem . 2002 ; 277 ( 15 ): 12689 - 96 .

Karikó K , Buckstein M , Ni H , Weissman D . Suppression of RNA recognition by toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA . Immunity . 2005 ; 23 ( 2 ): 165 - 75 .

Karikó K , Muramatsu H , Welsh FA , Ludwig J , Kato H , Akira S , et al . Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability . Mol Ther . 2008 ; 16 ( 11 ): 1833 - 40 .

Pardi N , Hogan MJ , Pelc RS , Muramatsu H , Andersen H , Demaso CR , et al . Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination . Nature . 2017 ; 543 ( 7644 ): 248 - 51 .

Zhang N , Channappanavar R , Ma C , Wang L , Tang J , Garron T , et al . Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus . Cell Mol Immunol . 2016 ; 13 ( 2 ): 180 - 90 .

Xie X , Liu Y , Liu J , Zhang X , Zou J , Fontes-Garfias CR , et al . Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera . Nat Med . 2021 ; 27 ( 4 ): 620 - 1 .

Amit S , Regev-Yochay G , Afek A , Kreiss Y , Leshem E . Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients . Lancet . 2021 ; 397 ( 10277 ): 875 - 7 .

Jimenez-Guardeño JM , Regla-Nava JA , Nieto-Torres JL , Dediego ML , Castano-Rodriguez C , Fernandez-Delgado R , et al . Identification of the mechanisms causing reversion to virulence in an attenuated SARS-CoV for the design of a genetically stable vaccine . PLoS Pathog . 2015 ; 11 ( 10 ): e1005215 .

Publication WHO . Polio vaccines and polio immunization in the pre-eradication era: WHO position paper-recommendations . Vaccine . 2010 ; 28 ( 43 ): 6943 - 4 .

Wu W , Liu D , Li K , Nuorti JP , Nohynek HM , Xu D , et al . Post-marketing safety surveillance for inactivated and live-attenuated Japanese encephalitis vaccines in China, 2008–2013 . Vaccine . 2017 ; 35 ( 29 ): 3666 - 71 .

Luo J , Wang X , Ma F , Kang G , Ding Z , Ye C , et al . Long-term immunogenicity and immune persistence of live attenuated and inactivated hepatitis a vaccines: a report on additional observations from a Phase IV study . Clin Microbiol Infect . 2019 ; 25 ( 11 ): 1422 - 7 .

Finke S , Karger A , Freuling C , Müller T . Assessment of inactivated human rabies vaccines: biochemical characterization and genetic identification of virus strains . Vaccine . 2012 ; 30 ( 24 ): 3603 - 9 .

Lim H , In HJ , Lee JA , Yoo JS , Lee SW , Chung GT , et al . The immunogenicity and protection effect of an inactivated coxsackievirus A6, A10, and A16 vaccine against hand, foot, and mouth disease . Vaccine . 2018 ; 36 ( 24 ): 3445 - 52 .

Qadri F , Ali M , Lynch J , Chowdhury F , Khan AI , Wierzba TF , et al . Efficacy of a single-dose regimen of inactivated whole-cell oral cholera vaccine: results from 2 years of follow-up of a randomised trial . Lancet Infect Dis . 2018 ; 18 ( 6 ): 666 - 74 .

Lin J , Zhang JS , Su N , Xu JG , Wang N , Chen JT , et al . Safety and immunogenicity from a Phase I trial of inactivated severe acute respiratory syndrome coronavirus vaccine . Antivir Ther . 2007 ; 12 ( 7 ): 1107 - 13 .

Pu J , Yu Q , Yin Z , Zhang Y , Li X , Yin Q , et al . The safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in Chinese adults aged 18–59 years: a phase I randomized, double-blinded, controlled trial . Vaccine . 2021 ; 39 ( 20 ): 2746 - 54 .

Poland GA , Ovsyannikova IG , Crooke SN , Kennedy RB . SARS-CoV-2 vaccine development: current status . Mayo Clin Proc . 2020 ; 95 ( 10 ): 2172 - 88 .

Koch T , Fathi A , Addo MM . The COVID-19 vaccine landscape . Adv Exp Med Biol . 2021 : 549 – 73 .

He Y , Zhu Q , Liu S , Zhou Y , Yang B , Li J , et al . Identification of a critical neutralization determinant of severe acute respiratory syndrome (SARS)-associated coronavirus: importance for designing SARS vaccines . Virology . 2005 ; 334 ( 1 ): 74 - 82 .

Ma C , Su S , Wang J , Wei L , Du L , Jiang S . From SARS-CoV to SARS-CoV-2: safety and broad-spectrum are important for coronavirus vaccine development . Microbes Infect . 2020 ; 22 ( 6–7 ): 245 - 53 .

Xiong S , Wang YF , Zhang MY , Liu XJ , Zhang CH , Liu SS , et al . Immunogenicity of SARS inactivated vaccine in BALB/c mice . Immunol Lett . 2004 ; 95 ( 2 ): 139 - 43 .

Gendon IuZ . Advantages and disadvantages of inactivated and live influenza vaccine . Vopr Virusol . 2004 ; 49 ( 4 ): 4 - 12 .

Xia S , Zhang Y , Wang Y , Wang H , Yang Y , Gao GF , et al . Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial . Lancet Infect Dis . 2021 . https://doi.org/10.1016/S1473-3099(21)00462-X https://doi.org/10.1016/S1473-3099(21)00462-X .

Torres TS , Luz PM , Coelho LE , Jalil C , Falco GG , Sousa LP , et al . SARS-CoV-2 testing disparities across geographical regions from a large metropolitan area in Brazil: results from a web-based survey among individuals interested in clinical trials for COVID-19 vaccines . Braz J Infect Dis . 2021 ; 25 ( 4 ): 101600 .

Maynard JE , Kane MA , Hadler SC . Global control of hepatitis B through vaccination: role of hepatitis B vaccine in the Expanded Programme on Immunization . Rev Infect Dis . 1989 ; 11 ( Suppl 3 ): S574 - 8 .

Haffar S , Bazerbachi F , Lake JR . Making the case for the development of a vaccination against hepatitis E virus . Liver Int . 2015 ; 35 ( 2 ): 311 - 6 .

de Oliveira CM , Fregnani JHTG , Villa LL . HPV vaccine: updates and highlights . Acta Cytol . 2019 ; 63 ( 2 ): 159 - 68 .

Morgado-Carrasco D , Fustà-Novell X , Giavedoni P . RF-new recombinant vaccine for the prevention of herpes zoster . Actas Dermosifiliogr (Engl Ed) . 2020 ; 111 ( 1 ): 67 - 8 .

Ma C , Li Y , Wang L , Zhao G , Tao X , Tseng CT , et al . Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: Implication for designing novel mucosal MERS vaccines . Vaccine . 2014 ; 32 ( 18 ): 2100 - 8 .

Harper DM , DeMars LR . HPV vaccines—a review of the first decade . Gynecol Oncol . 2017 ; 146 ( 1 ): 196 - 204 .

Ma C , Wang L , Tao X , Zhang N , Yang Y , Tseng CT , et al . Searching for an ideal vaccine candidate among different MERS coronavirus receptor-binding fragments—the importance of immuno-focusing in subunit vaccine design . Vaccine . 2014 ; 32 ( 46 ): 6170 - 6 .

Wang SF , Tseng SP , Yen CH , Yang JY , Tsao CH , Shen CW , et al . Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins . Biochem Biophys Res Commun . 2014 ; 451 ( 2 ): 208 - 14 .

Kim HW , Canchola JG , Brandt CD , Pyles G , Chanock RM , Jensen K , et al . Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine . Am J Epidemiol . 1969 ; 89 ( 4 ): 422 - 34 .

Graham BS . Vaccines against respiratory syncytial virus: the time has finally come . Vaccine . 2016 ; 34 ( 30 ): 3535 - 41 .

Nader PR , Horwitz MS , Rousseau J . Atypical exanthem following exposure to natural measles: eleven cases in children previously inoculated with killed vaccine . J Pediatr . 1968 ; 72 ( 1 ): 22 - 8 .

Polack FP . Atypical measles and enhanced respiratory syncytial virus disease (ERD) made simple . Pediatr Res . 2007 ; 62 ( 1 ): 111 - 5 .

Lee WS , Wheatley AK , Kent SJ , Dekosky BJ . Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies . Nat Microbiol . 2020 ; 5 ( 10 ): 1185 - 91 .

Arvin AM , Fink K , Schmid MA , Cathcart A , Spreafico R , Havenar-Daughton C , et al . A perspective on potential antibody-dependent enhancement of SARS-CoV-2 . Nature . 2020 ; 584 ( 7821 ): 353 - 63 .

Li D , Edwards RJ , Manne K , Martinez DR , Schäfer A , Alam SM , et al . In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies . Cell . 2021 ; 184 ( 16 ): 4203-19.e32 .

Bournazos S , Gupta A , Ravetch JV . The role of IgG Fc receptors in antibody-dependent enhancement . Nat Rev Immunol . 2020 ; 20 ( 10 ): 633 - 43 .

Haynes Barton F , Corey L , Fernandes P , Gilbert Peter B , Hotez Peter J , Rao S , et al . Prospects for a safe COVID-19 vaccine . Sci Transl Med . 2020 ; 12 ( 568 ): eabe0948 .

Iwasaki A , Yang Y . The potential danger of suboptimal antibody responses in COVID-19 . Nat Rev Immunol . 2020 ; 20 ( 6 ): 339 - 41 .

Fynan EF , Lu S , Robinson HL . One group’s historical reflections on DNA vaccine development . Hum Gene Ther . 2018 ; 29 ( 9 ): 966 - 70 .

Goepfert PA , Fu B , Chabanon AL , Bonaparte MI , Davis MG , Essink BJ , et al . Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1–2, dose-ranging study . Lancet Infect Dis . 2021 ; 21 ( 9 ): 1257 - 70 .

Hu J , Wang M , Xiao X , Zhang B , Xie Q , Xu X , et al . A novel long-acting azathioprine polyhydroxyalkanoate nanoparticle enhances treatment efficacy for systemic lupus erythematosus with reduced side effects . Nanoscale . 2020 ; 12 ( 19 ): 10799 - 808 .

Chen R , Yu J , Gong HL , Jiang Y , Xue M , Xu N , et al . An easy long-acting BMP7 release system based on biopolymer nanoparticles for inducing osteogenic differentiation of adipose mesenchymal stem cells . J Tissue Eng Regen Med . 2020 ; 14 ( 7 ): 964 - 72 .

Rahman M , Peng XL , Zhao XH , Gong HL , Sun XD , Wu Q , et al . 3D bioactive cell-free-scaffolds for in-vitro/in-vivo capture and directed osteo-induction of stem cells for bone tissue regeneration . Bioact Mater . 2021 ; 6 ( 11 ): 4083 - 95 .

Keshavarz T , Roy I . Polyhydroxyalkanoates: bioplastics with a green agenda . Curr Opin Microbiol . 2010 ; 13 ( 3 ): 321 - 6 .

Parlane NA , Gupta SK , Rubio-Reyes P , Chen S , Gonzalez-Miro M , Wedlock DN , et al . Self-assembled protein-coated polyhydroxyalkanoate beads: properties and biomedical applications . ACS Biomater Sci Eng . 2016 ; 3 ( 12 ): 3043 - 57 .

Wei DX , Dao JW , Chen GQ . A micro-ark for cells: highly open porous polyhydroxyalkanoate microspheres as injectable scaffolds for tissue regeneration . Adv Mater . 2018 ; 30 ( 31 ): e1802273 .

Wei DX , Dao JW , Liu HW , Chen GQ . Suspended polyhydroxyalkanoate microspheres as 3D carriers for mammalian cell growth . Artif Cells Nanomed Biotechnol . 2018 ; 46 ( sup2 ): 473 - 83 .

Wei D , Qiao R , Dao J , Su J , Jiang C , Wang X , et al . Soybean lecithin-mediated nanoporous PLGA microspheres with highly entrapped and controlled released BMP-2 as a stem cell platform . Small . 2018 ; 14 ( 22 ): 1800063 .

Martínez-Donato G , Piniella B , Aguilar D , Olivera S , Perez A , Castanedo Y , et al . Protective T cell and antibody immune responses against hepatitis C virus achieved using a biopolyester-bead-based vaccine delivery system . Clin Vaccine Immunol . 2016 ; 23 ( 4 ): 370 - 8 .

Wei DX , Chen CB , Fang G , Li SY , Chen GQ . Application of polyhydroxyalkanoate binding protein PhaP as a bio-surfactant . Appl Microbiol Biotechnol . 2011 ; 91 ( 4 ): 1037 - 47 .

Walls AC , Fiala B , Schäfer A , Wrenn S , Pham MN , Murphy M , et al . Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2 . Cell . 2020 ; 183 ( 5 ): 1367-82. e17 .

Zhang B , Chao CW , Tsybovsky Y , Abiona OM , Hutchinson GB , Moliva JI , et al . A platform incorporating trimeric antigens into self-assembling nanoparticles reveals SARS-CoV-2-spike nanoparticles to elicit substantially higher neutralizing responses than spike alone . Sci Rep . 2020 ; 10 ( 1 ): 18149 .

Lopez Bernal J , Andrews N , Gower C , Gallagher E , Simmons R , Thelwall S , et al . Effectiveness of COVID-19 vaccines against the B. 1.617. 2 (delta) variant . N Engl J Med . 2021 : 585 – 94 .

de Vrieze J . Pfizer’s vaccine raises allergy concerns . Science . 2021 ; 371 ( 6524 ): 10 - 1 .